Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Chronic Heart Failure Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Chronic Heart Failure Overview | 10 | 1 |
| Pipeline Products for Chronic Heart Failure Comparative Analysis | 11 | 1 |
| Chronic Heart Failure Therapeutics under Development by Companies | 12 | 2 |
| Chronic Heart Failure Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Chronic Heart Failure Pipeline Products Glance | 15 | 3 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Chronic Heart Failure Products under Development by Companies | 18 | 1 |
| Chronic Heart Failure Products under Investigation by Universities/Institutes | 19 | 1 |
| Chronic Heart Failure Companies Involved in Therapeutics Development | 20 | 18 |
| Amgen Inc. | 20 | 1 |
| AnGes MG, Inc. | 21 | 1 |
| AstraZeneca Plc | 22 | 1 |
| Bayer AG | 23 | 1 |
| Capricor Therapeutics, Inc. | 24 | 1 |
| Celyad SA | 25 | 1 |
| Juventas Therapeutics, Inc. | 26 | 1 |
| Laboratoires Pierre Fabre SA | 27 | 1 |
| Les Laboratoires Servier SAS | 28 | 1 |
| Mast Therapeutics, Inc. | 29 | 1 |
| Mesoblast Limited | 30 | 1 |
| Novartis AG | 31 | 1 |
| Pfizer Inc. | 32 | 1 |
| scPharmaceuticals Inc | 33 | 1 |
| Stemedica Cell Technologies, Inc. | 34 | 1 |
| Theravance Biopharma, Inc. | 35 | 1 |
| Vichem Chemie Research Ltd. | 36 | 1 |
| Zensun (Shanghai) Sci &Tech Co., Ltd. | 37 | 1 |
| Chronic Heart Failure Therapeutics Assessment | 38 | 10 |
| Assessment by Monotherapy Products | 38 | 1 |
| Assessment by Combination Products | 39 | 1 |
| Assessment by Target | 40 | 2 |
| Assessment by Mechanism of Action | 42 | 2 |
| Assessment by Route of Administration | 44 | 2 |
| Assessment by Molecule Type | 46 | 2 |
| Drug Profiles | 48 | 91 |
| (sacubitril + valsartan) Drug Profile | 48 | 5 |
| beperminogene perplasmid Drug Profile | 53 | 5 |
| C3BSCQR-1 Drug Profile | 58 | 5 |
| cenderitide Drug Profile | 63 | 3 |
| CLR-325 Drug Profile | 66 | 1 |
| dapagliflozin propanediol Drug Profile | 67 | 7 |
| F-373280 Drug Profile | 74 | 1 |
| furosemide Drug Profile | 75 | 2 |
| ivabradine hydrochloride Drug Profile | 77 | 2 |
| JVS-100 Drug Profile | 79 | 4 |
| L-2286 Drug Profile | 83 | 1 |
| MPC-150IM Drug Profile | 84 | 5 |
| neladenoson bialanate Drug Profile | 89 | 1 |
| Neucardin Drug Profile | 90 | 3 |
| omecamtiv mecarbil MR Drug Profile | 93 | 7 |
| rivaroxaban Drug Profile | 100 | 14 |
| S-38844 Drug Profile | 114 | 1 |
| serelaxin Drug Profile | 115 | 4 |
| sildenafil citrate Drug Profile | 119 | 2 |
| Small Molecules for Chronic Heart Failure Drug Profile | 121 | 1 |
| Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile | 122 | 6 |
| Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases Drug Profile | 128 | 1 |
| TD-1439 Drug Profile | 129 | 1 |
| vepoloxamer Drug Profile | 130 | 8 |
| vericiguat Drug Profile | 138 | 1 |
| Chronic Heart Failure Dormant Projects | 139 | 2 |
| Chronic Heart Failure Discontinued Products | 141 | 1 |
| Chronic Heart Failure Product Development Milestones | 142 | 13 |
| Featured News &Press Releases | 142 | 1 |
| Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients | 142 | 1 |
| Sep 19, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting | 143 | 1 |
| Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure | 144 | 1 |
| Sep 09, 2016: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting | 144 | 1 |
| Sep 01, 2016: Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development | 145 | 1 |
| Aug 28, 2016: CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications | 145 | 2 |
| Jul 01, 2016: Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations | 147 | 1 |
| Jun 28, 2016: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy | 148 | 1 |
| Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology | 149 | 1 |
| Jun 14, 2016: Mesoblast Provides Update On Global Heart Failure Program | 150 | 1 |
| May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress | 151 | 1 |
| May 23, 2016: Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure | 151 | 1 |
| May 13, 2016: Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016 | 152 | 1 |
| Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition | 153 | 1 |
| Apr 26, 2016: Celyad receives certification for C-Cure non-clinical data from the European Medicines Agency | 154 | 1 |
| Appendix | 155 | 2 |
| Methodology | 155 | 1 |
| Coverage | 155 | 1 |
| Secondary Research | 155 | 1 |
| Primary Research | 155 | 1 |
| Expert Panel Validation | 155 | 1 |
| Contact Us | 155 | 1 |
| Disclaimer | 156 | 1 |